U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080775) titled 'The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease' on July 09.
Brief Summary: This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease
Study Start Date: July 25
Study Type: INTERVENTIONAL
Condition:
Parkinson's Disease
Intervention:
DRUG: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection
5.0x10^7 cells/mL, injection, once, 12 months
Recruitment Status: NOT_YET_RECRUITING
Sponsor: ...